- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Fostamatinib, Ruxolitinib
- Drug
- Lead sponsor
- Stefanie Sarantopoulos, MD, PhD.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 959
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- MM-151, MM-121, MM-141, trametinib
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more
- Conditions
- Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
- Interventions
- INZ-701, Control Arm (Conventional Therapy)
- Drug
- Lead sponsor
- Inozyme Pharma
- Industry
- Eligibility
- 1 Year to 12 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania • Fort Worth, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
- Interventions
- revumenib, cobicistat
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 30 Days and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 22
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 17 more
- Conditions
- Multiple Myeloma
- Interventions
- PDR001, CJM112, LCL161
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Nashville, Tennessee
- Conditions
- Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis, Acute Lymphoblastic Leukemia, Chronic Myelocytic Leukemia, Non Hodgkins Lymphoma, Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day
- Drug
- Lead sponsor
- Tarix Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- SNV4818, Fulvestrant, Palbociclib
- Drug
- Lead sponsor
- Pikavation Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
- Drug
- Lead sponsor
- American Society of Clinical Oncology
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 92
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 79 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
- Interventions
- NOX66, EBRT
- Drug · Radiation
- Lead sponsor
- Noxopharm Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Houston, Texas
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
- Interventions
- Enzelkitug, Atezolizumab, Pembrolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 10
- States / cities
- San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Dexamethasone, Aspirin
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more
- Conditions
- Colorectal Carcinoma
- Interventions
- MGD007
- Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Tampa, Florida • Baltimore, Maryland + 4 more
- Conditions
- Obesity, Obesity; Drug, Lifestyle, Healthy
- Interventions
- Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG
- Behavioral · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Saint Louis Park, Minnesota • Winston-Salem, North Carolina + 1 more
- Conditions
- Breast Neoplasms, Breast Cancer, Estrogen-receptor Positive Breast Cancer, Cancer, Breast, Breast Cancer Female, Breast Adenocarcinoma, Estrogen Receptor Positive Tumor, ER Positive
- Interventions
- H3B-6545
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 23
- States / cities
- Goodyear, Arizona • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Traumatic Brain Injury
- Interventions
- SLV334, Placebo
- Drug
- Lead sponsor
- Abbott Products
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Dayton, Ohio • Portland, Oregon + 1 more
- Conditions
- Neuroblastoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania
- Conditions
- Breakthrough Pain
- Interventions
- Inhaled Placebo, Inhaled Fentanyl 25 mcg, Intravenous Fentanyl 25 mcg, Inhaled Fentanyl 25 mcg x 2, Inhaled Fentanyl 25 mcg x 4, Inhaled Fentanyl 25 mcg x 6, Inhaled Fentanyl 25 mcg x 12
- Drug
- Lead sponsor
- Alexza Pharmaceuticals, Inc.
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lymphoma, Solid Tumor
- Interventions
- GDC-0575, Gemcitabine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Interventions
- BPX-701, Rimiducid
- Biological · Drug
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Portland, Oregon • Nashville, Tennessee
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- CP-751,871, paclitaxel, carboplatin, erlotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more
- Conditions
- Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
- Interventions
- Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE, GEMCITABINE
- Procedure · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib)
- Drug
- Lead sponsor
- Adagene Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more
- Conditions
- Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
- Interventions
- Norovirus -specific T-cell (NST) therapy
- Biological
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Months to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland